INS and cancer: Metformin and TZDs have been reported for antitumorigenic effects either as a single agent or in combination with conventional chemotherapeutic agents because of the reduction of insulin and the modulation of intracellular drug targets and epidemiologically both are reported to be associated with low cancer incidence rates [265,266,267].